For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Fluorescent carbon dots could make cancer treatment safer and more effectiveon August 16, 2019 at 6:46 am
The next stage of our work is the translation of our findings to more complex models of cancer and ultimately to patients.” Jose Ricardo Aguilar Cosme, a PhD Engineering Materials student, said: “The ...
- Tiny "glass bottles" deliver drugs on demand when heatedon August 14, 2019 at 11:58 pm
Cancer drugs are getting more effective at ... The design of the new drug delivery system is quite clever. The "bottles" are hollow spheres made of silica and measuring about 200 nanometers ...
- Nanocapsule reaches cancer that has spread to central nervous system in miceon August 14, 2019 at 2:11 pm
Cancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in ...
- Advanced Parenteral Drug Delivery Devices Market Insights, Global Industry Analysis, Size, Share, Trends and Forecast, 2014 – 2024on August 14, 2019 at 1:26 am
and cancer; the growing focus on pediatric and geriatric patients; and the increasing demand for minimally invasive surgeries are other factors contributing to growth in the drug delivery market. In ...
- Worldwide Fallopian Tube Cancer Therapeutics Market Insights (2019-2023): Increasing Number of Drug Approvals Spurring Market Growthon August 14, 2019 at 12:45 am
These factors help nanoparticles to be an effective drug delivery for the administration of chemotherapy ... Also, our global fallopian tube cancer therapeutics market report also looks at factors ...
- Gold Nanoparticles as Promising Drug-Delivery System to Target Cancer Biomarkerson August 12, 2019 at 7:29 am
Targeted drug-delivery systems are a promising candidate for the effective treatment of cancer by leaving the healthy surrounding tissues unaffected. However, they can work only when the drug hits its ...
- Topical Drug Delivery Market Worth $123.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™on August 9, 2019 at 4:38 am
Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), ...
- Self-assembled hyaluronan nanocapsules for the intracellular delivery of anticancer drugson August 9, 2019 at 2:30 am
Furthermore, in vitro studies performed using A549 lung cancer cells, showed effective intracellular ... the potential of self-emulsifying HA nanocapsules for intracellular drug delivery. Dodecylamide ...
- Brain-targeted drug delivery by manipulating protein corona functionson August 8, 2019 at 2:30 am
The brain targeting efficiency and anti-brain cancer effect of doxorubicin-loaded SP-sLip (SP ... theoretically possible to be utilized to reengineer the nano-surface of drug delivery systems. HSPC ...
via Bing News